• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Zepbound, Shaquille O`Neal Launch Sleep Apnea Awareness Push

    PR NEWSWIRE

    CVS Caremark Expands Coverage for GLP-1 Weight Management

    ACCESSWIRE

    India`s GLP-1 Market Cools After Initial Semaglutide Surge

    BUSINESS STD

    MitoRx Shows MTRX31 Preclinical Data for Metabolic Obesity at ADA

    GLOBENEWSWIRE

    Lilly`s Oral GLP-1 Foundayo Excels in Three Phase 3 Trials

    PR NEWSWIRE

    Lilly`s Weight Loss Drug Shows Benefits in Menopause, Sleep Apnea

    PR NEWSWIRE

    Corcept Presents ADA Data on Korlym® in T2D with Hypercortisolism

    PRESS RELEASE

    Lilly`s Foundayo Drives Weight Loss Across Menopause Stages

    PR NEWSWIRE

    Semaglutide 2mg Rivals Tirzepatide in HbA1c & Weight Loss in T2D

    PR NEWSWIRE

    CVS Restores Zepbound Coverage, Adds New Pill Foundayo

    FIERCE PHARMA

    Lilly to Present Foundayo, Mounjaro Data at ADA 2026

    PR NEWSWIRE

    Ondra Health Launches Nationwide GLP-1 Weight Loss Platform

    BUSINESSWIRE

    Ozari Health Releases New Industry Research on GLP-1 Pricing

    GLOBENEWSWIRE

    OTC Phentermine Alternatives 2026: PhenQ Assessed via SCALE-9

    GLOBENEWSWIRE

    Ozari Health Launches Telehealth for Semaglutide from $86/Month

    GLOBENEWSWIRE

    Caliway: CBL-514 Preclinical Data Presented at ECO 2026

    PR NEWSWIRE

    Clearmind Medicine to Study MEAI with Tirzepatide vs GLP-1 Drugs

    GLOBENEWSWIRE

    India’s Counterfeit Drug Crisis & Role of AI

    EXPRESSPHARMA

    Lilly Sustains Weight Loss Lead With Foundayo, Zepbound

    BIOSPACE

    Generic Entry Sparks GLP-1 Boom in India

    PHARMABIZ

    Lilly Eyes Low-Dose Zepbound, Foundayo for Weight Loss

    ENDPOINTS

    Novi GLP-1 Weight Loss Options Evaluated With Dedicated Doctors

    GLOBENEWSWIRE

    Biotech`s Next Wave May Already Be In Motion

    GLOBENEWSWIRE

    Affordable Semaglutide & Tirzepatide GLP-1 Program Assessed

    GLOBENEWSWIRE

    U.S. Prescription Drug Spending Poised To Cross $1 Trillion

    PR NEWSWIRE

    FDA Proposes Excluding Semaglutide, Tirzepatide, Liraglutide

    FDA

    Lilly Backs Haryana State-Fda Against Counterfeit Medicines

    EXPRESSPHARMA

    Experts Scrutinize SkinnyRx`s GLP-1 Semaglutide Claims

    GLOBENEWSWIRE

    Roche Backs Amylin Drug for Low-Side-Effect Obesity Care

    BIOSPACE

    Different Packaging, Typos Expose Fake Mounjaro Racket

    ECONOMICTIMES

    FDA issues warning letter after GLP-1 manufacturer

    FDA

    Eli Lilly Issues Statement On Counterfeit Mounjaro Case

    ECONOMICTIMES

    Eli Lilly flags counterfeit Mounjaro seizure in Gurugram

    INDPHARMAPOST

    Ozempic, Mounjaro Weight-Loss Drug Demand Surges In India

    ECONOMICTIMES

    Study Suggests Lilly`s Tirzepatide Causes More Lean Muscle Loss

    ENDPOINTS

    Retatrutide Ignites Buzz on Weight Loss, Longevity

    ECONOMICTIMES

    Mounjaro Sales Decline Due To Semaglutide Generics` Rise

    ECONOMICTIMES

    Vanda Kicks Off NEREUS Trial for GLP-1-Induced Nausea

    PR NEWSWIRE

    Generic Drugmakers Rush As Novo Nordisk Loses Weight-Loss Drug

    ECONOMICTIMES

    23andMe Study Identifies Genetic Predictors of GLP-1 Weight Loss

    GLOBENEWSWIRE

    Weight-Loss Injections Integrated Into Indian `Mounjaro Brides`

    ECONOMICTIMES

    Lilly Taltz, Zepbound Show Strong PsA, Obesity Efficacy

    PR NEWSWIRE

    ReflexMD Evaluates Safety Risks Of GLP-1 Claims For Semaglutide

    GLOBENEWSWIRE

    Kroger Introduces Zepbound Kwikpen To Retail, Enhancing Access

    PR NEWSWIRE

    Novo Nordisk Boosts Semaglutide Over Eli Lilly In Market Share

    ECONOMICTIMES

    GoodRx To Expand Employer-Sponsored Access To Zepbound Kwikpen

    PHARMIWEB

    Lilly Launches Employer Connect Platform With 15 Administrators

    PR NEWSWIRE

    Ahead Of Its Time, A GLP-1 Drug Almost Made It Out Of India

    ECONOMICTIMES

    Eli Lilly Holds Premium Price Ahead of Generic Rivals

    ECONOMICTIMES

    What to Know Before Enrolling in MEDVi Tirzepatide GLP-1 Program

    GLOBENEWSWIRE

    Sprout Health Unveils 2026 GLP-1 Weight Loss Program

    GLOBENEWSWIRE

    Lilly to Launch Multi-Dose Weight-Loss Drug Device in US

    REUTERS

    Lilly`s Taltz And Zepbound Show Superior Efficacy In Psoriasis

    PR NEWSWIRE

    Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I

    BIOSPACE

    Allurion Partners For Discounted Mounjaro Combination Therapy

    BUSINESSWIRE

    Utide Tirzepatide, Retatrutide Clear US DMF Filing

    PRESS RELEASE

    Skye Showcases Peripherally-Restricted CB1 Inhibitor Antibody

    GLOBENEWSWIRE

    Skye Bioscience To Present Poster At Keystone Obesity Conference

    GLOBENEWSWIRE

    CoreAge Rx Expands GLP-1 Access For New Year Weight Loss Goals

    PR NEWSWIRE

    BoomRx Launches Oral Semaglutide & Tirzepatide Nationwide

    PR NEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.